DRG Market Assessment reports

Clarivate Epidemiology’s coverage of Rett syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of Angelman syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Myasthenia gravis (MG) is a rare neuromuscular disorder primarily caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…

Clarivate Epidemiology’s coverage of spinocerebellar ataxia (SCA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Lennox-Gastaut syndrome (LGS) is a severe pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities…

Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…

Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…

Clarivate Epidemiology’s coverage of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related neuropathy comprises epidemiological estimates of key patient populations…

Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…

Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…

Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…